---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-175494"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:43:49.686614+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports Q2 net loss $115.6M; PDUFA for paltusotine on Sept 25, 2025

## Summary
- Revenue $1.0M (vs $0.4M in Q2 2024); net loss widened to $115.6M from $74.1M YoY.
- Cash, cash equivalents & investments $1.2B as of June 30, 2025; expected runway into 2029.
- Paltusotine NDA PDUFA target action date September 25, 2025 for acromegaly; EMA review expected H1 2026.
- Upcoming Phase 3 starts in H2 2025 for paltusotine in carcinoid syndrome and atumelnant in CAH (adult and pediatric).
- 2025 cash used in operations guided at $340-370M.

## SEC filing metadata
- accession: 0001193125-25-175494
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/0001193125-25-175494-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312525175494/crnx-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-175494
- JSON: https://secwatch.observer/filing/0001193125-25-175494.json
- Plain text: https://secwatch.observer/filing/0001193125-25-175494.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.